NEW YORK, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of VimpelCom Ltd. (NASDAQ:VIP) securities during the period from June 30, 2011 through November 2, 2015 inclusive (the “Class Period”) of the important January 4, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for VimpelCom investors under the federal securities laws.
To join the VimpelCom class action, go to the firm’s website at http://www.rosenlegal.com/cases-774.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants made false and/or misleading statements and/or failed to disclose that: (i) VimpelCom had paid tens of millions of dollars to a company controlled by Gulnara Karimova (“Karimova”), daughter of the president of Uzbekistan; (ii) the payments to Karimova were unlawful bribes intended to secure VimpelCom’s access to Uzbekistan’s telecommunications market; and (iii) as a result of the foregoing, Defendants’ statements about VimpelCom’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
On November 3, 2015, pre-market, VimpelCom announced that it had set aside $900 million for litigation costs in connection with U.S. and Dutch investigations into the Company’s operations in Uzbekistan. On this news, VimpelCom’s ADRs fell $0.17, or 4.63%, to close at $3.50 on November 3, 2015.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 4, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-774.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 



